Animal study yields promising results for measles drug

Measles vaccination gaps have stalled efforts to further reduce the burden of the disease, but early results from animal tests suggest that health departments may someday have an oral drug to help knock down outbreaks.

The encouraging findings come at a time when health officials in many countries scramble to extinguish outbreaks, most recently in the Fraser Valley of British Columbia, California, New York City, and even a cruise ship in Europe.

The team tested the new drug, a small-molecule RNA polymerase inhibitor known as ERDRP-0519, in ferrets exposed to a lethal challenge with canine distemper virus (CDV), another morbillivirus that is closely related to measles. Led by researchers from Georgia State University (GSU), the international group of scientists published their findings today in the latest online edition of Science Translational Medicine.

Richard Plemper, PhD, one of the authors of the study, said at a media briefing yesterday that over the past decades, deaths from measles dropped in number but have plateaued at around 150,000 per year since about 2007 because of vaccine coverage gaps—access problems in the developing world and parental suspicions about vaccines in developed nations. He is a professor in the Center for Inflammation, Immunity, and Infection at GSU.

He emphasized that the drug, if it proceeds smoothly through further animal and human trials, isn’t intended as a replacement for the vaccine but rather as a tool that can dovetail with measles vaccination programs. The group envisions that the shelf-stable drug could be stockpiled and used to stem measles outbreaks in settings where vaccination rates fall below critical thresholds.

Global control of measles must center on high vaccination coverage, Plemper said. “We were developing here an additional regimen against the virus that, combined [with immunization], should help us win the endgame of eradication.”

During measles infections, the rash typically develops after the body’s immune response has cleared most of the virus, so the drug would best be used in nonvaccinated social contacts of confirmed cases during the 2-week period before clinical signs develop, he said.

It isn’t clear how costly the drug would be, he said, but he added that the novel compound is one the pharmaceutical industry can produce with established facilities and at a competitive price.

Veronika von Messling, DVM, with the Paul-Ehrlich-Institut in Langen, Germany, who is one of the study coauthors, told reporters that the study results have also prompted researchers to discuss if it would be useful to develop the drug for treating CDV in animals.

FOLLOW THE CIDRAP POST HERE.

FOLLOW THE ORIGINAL SCIENTIFIC ARTICLE HERE.

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: